New Drugs Recognized as a 'Major Shift' in Combating Drug-Resistant Gonorrhoea

The recently developed medications for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the effort against increasingly resistant strains of the infection, according to health experts.

A Worldwide Public Health Issue

Cases of gonorrhoea are on the rise worldwide, with data suggesting in excess of 82 million new cases annually. Particularly high rates are reported in Africa and countries within the WHO's designated area, which includes Mongolia and China to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary advancement in the context of increasing worldwide cases, increasing antimicrobial resistance and the very limited available drugs currently available.”

Public health authorities are increasingly worried about the increase in drug-resistant strains. The WHO has listed it as a "high-priority threat". Ongoing monitoring found that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Gain Approval

Zoliflodacin, alternatively called a brand name, was approved by the US FDA in mid-December for use against gonorrhoea. This infection can lead to major issues, including infertility. Researchers hope that targeted use of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the drugmaker GSK, was also approved in the same week. This treatment, which is also used to treat UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This approval represents a huge turning point in the therapy of multidrug-resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Testing Data and Worldwide Availability

Based on results released by a prominent scientific publication, the new drug successfully treated the vast majority of uncomplicated infections. This places it at an comparable level with the existing first-line therapy, which combines an injection and a pill. The study included over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the rights to license and sell the drug in numerous developing nations.

Medical professionals directly involved have shared positive views. The availability of a easy-to-administer therapy such as this is described as a "critical tool" for public health efforts. This is considered crucial to alleviate the strain of the infection for individuals and to halt the transmission of untreatable gonorrhoea worldwide.